H.C. Wainwright names Pacira BioSciences a top pick for 2024 and reiterates a Buy rating on the shares with a $57 price target. The stock is trading near 10-year lows and near all-time low forward multiples, the analyst tells investors in a research note. The firm believes there is a “compelling disconnect” between the current valuation and the company’s “robust cash flows, low leverage, and likely a very long exclusivity runway.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PCRX:
- Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2023 Revenues
- Pacira reports preliminary FY23 revenue $675M, consensus $677.3M
- Pacira BioSciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Pacira Appoints Frank D. Lee as Chief Executive Officer
- Pacira appoints Frank Lee as CEO
